Skip to main content
Equibles
SYRE logo

SYRE · Spyre Therapeutics, Inc.

Track SYRE — free

Use SYRE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$87.25 +0.20 (+0.23%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”
View the 10-Q filed Aug 4, 2026
Market Cap
$7.54B
Shares
88.17M

SYRE metrics

51 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$87.05
Market cap
$7.54B

Price action

19 metrics
Price change (1W)
-7.0%
Price change (30D)
-17.0%
Price change (3M)
+18.4%
Price change (6M)
+112.3%
Price change (YTD)
+165.7%
Price change (1Y)
+423.5%
Trailing year
Price change (5Y)
—
52-week high
$108.92
52-week low
$14.82
Change from 52-week high
-20.1%
Change from 52-week low
+487.4%
Annualized volatility
70.0%
Beta
1.9
RSI (14D)
32.3
Price vs SMA 50
-11.2%
Price vs SMA 200
+41.9%
Avg volume (3M)
1.33M
Relative volume
1.0
Average dollar volume
$123.34M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
88.17M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.8
reciprocal yield 14.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2020-02-24

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$201.34M
Net income (TTM)
−$178.92M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-733.06

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,085.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-16.2%
Return on assets
-15.3%
Debt / equity
—
Current ratio
18.5
EBITDA (TTM)
−$208.57M
Free cash flow (TTM)
—
Quick ratio
18.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$162.01M
Total assets
$1.17B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$208.94M
Capital expenditures (TTM)
$38,000
R&D (TTM)
$215.80M
SG&A (TTM)
—
Stock compensation (TTM)
$45.70M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
268
13F filer change QoQ
+75
Institutional ownership
109.4%

Short interest

3 metrics
Short interest
13.3%
Latest settlement · 16.0 days to cover
Days to cover
16.0d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$410.22M
Insider-sentiment score
10 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1636282 CUSIP 00773J202 13F (30d) 237 filings 234 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)